TLDR
- Centene stock plunged 14% on Tuesday, ranking as the S&P 500’s biggest loser that session
- ACA membership projected to fall to 3.5 million by Q1’s close, a steep decline from December’s 5.5 million
- Management maintained its adjusted EPS forecast of above $3 for 2026
- Mizuho slashed its price target from $47 down to $41, keeping a Neutral stance
- Medicare Advantage profitability continues bleeding, with negative margins expected through 2026
Investors in Centene faced another brutal session Tuesday as the healthcare insurer’s shares plummeted 14% following concerning remarks from CEO Sarah London at the Barclays Global Healthcare Conference. Her acknowledgment of steep enrollment losses sent shockwaves through the market.
During her presentation, London reassured attendees that Centene’s three primary business segments remain positioned to meet 2026 targets. She stood by the company’s adjusted earnings projection of more than $3 per share — aligned with the $3 consensus from FactSet analysts.
Yet the market reaction was anything but positive. Without any guidance upgrade, investors fixated on troubling membership trends.
The health insurer now forecasts ending the first quarter with just 3.5 million Affordable Care Act marketplace enrollees, representing a dramatic fall from December’s 5.5 million. As of last month, membership stood at 3.6 million.
London indicated Centene had projected the marketplace would contract “somewhere between the high teens and the mid-thirties” on a percentage basis. She noted the company anticipated landing “at the higher end of that and possibly higher than the top end of that.”
She explained that strategic pricing adjustments implemented early this year contributed to the decline, with Centene choosing to emphasize profitability improvements rather than chasing membership volume.
Medicare Advantage Profitability Remains Elusive
The company’s Medicare Advantage segment remains a significant headwind. This business line posted negative margins throughout 2025 and will likely stay marginally unprofitable during 2026, with profitability targets pushed to 2027.
Adding to investor anxiety is the pending final rate announcement from the Centers for Medicare and Medicaid Services, scheduled for no later than April 6. The Trump administration’s earlier proposal to maintain essentially flat Medicare rates in 2027 dealt a blow to Centene and industry competitors.
London revealed the company filed comments with CMS regarding the Advance Rate Notice and voiced optimism that final rates would better account for recent medical cost inflation affecting the sector.
Wall Street Responds
Mizuho wasted no time adjusting its outlook following the conference. The investment firm lowered Centene’s price target to $41 from $47 while maintaining its Neutral rating.
Mizuho pointed to worries surrounding health insurance exchange member attrition and specialty pharmaceutical trends. The firm indicated it’s applying a more cautious valuation approach until greater transparency emerges around the enrollment deterioration.
Truist Securities took a less pessimistic stance, preserving its Buy rating with a $49 price objective, highlighting margin expansion potential and leadership conviction. Cantor Fitzgerald maintained a Neutral rating with a $41 target, characterizing the 2026 operating landscape as difficult.
For perspective, Centene has declined 9.7% in 2026, compared to a modest 0.7% drop for the broader S&P 500.
The stock has nonetheless outperformed several competitors. Molina Healthcare has fallen 17% year-to-date, Elevance Health is down 18%, and UnitedHealth Group has shed 14%.
Centene’s fourth quarter 2025 results revealed an adjusted diluted loss per share of $1.19, narrowly beating the anticipated $1.22 loss. Revenue reached $49.73 billion, surpassing the $48.39 billion estimate.
InvestingPro values Centene’s fair value at $62.11, with Wall Street analysts forecasting EPS of $3.05 for the complete 2026 fiscal year.
